Login / Signup

A cell state-specific metabolic vulnerability to GPX4-dependent ferroptosis in glioblastoma.

Matei A BanuAthanassios DovasMichael G ArgenzianoWenting ZhaoColin P SperringHenar Cuervo GrajalZhouzerui LiuDominique Mo HigginsMisha AminiBrianna PereiraLing F YeAayushi MahajanNelson HumalaJulia L FurnariPavan S UpadhyayulaFereshteh ZandkarimiTrang Thi Thu NguyenDamian TeasleyPeter B WuLi HaiCharles KaranTyrone DowdyAida RazavilarMarkus D SiegelinJan KitajewskiMioara LarionJeffrey N BruceBrent R StockwellPeter A SimsPeter D Canoll
Published in: The EMBO journal (2024)
Glioma cells hijack developmental programs to control cell state. Here, we uncover a glioma cell state-specific metabolic liability that can be therapeutically targeted. To model cell conditions at brain tumor inception, we generated genetically engineered murine gliomas, with deletion of p53 alone (p53) or with constitutively active Notch signaling (N1IC), a pathway critical in controlling astrocyte differentiation during brain development. N1IC tumors harbored quiescent astrocyte-like transformed cell populations while p53 tumors were predominantly comprised of proliferating progenitor-like cell states. Further, N1IC transformed cells exhibited increased mitochondrial lipid peroxidation, high ROS production and depletion of reduced glutathione. This altered mitochondrial phenotype rendered the astrocyte-like, quiescent populations more sensitive to pharmacologic or genetic inhibition of the lipid hydroperoxidase GPX4 and induction of ferroptosis. Treatment of patient-derived early-passage cell lines and glioma slice cultures generated from surgical samples with a GPX4 inhibitor induced selective depletion of quiescent astrocyte-like glioma cell populations with similar metabolic profiles. Collectively, these findings reveal a specific therapeutic vulnerability to ferroptosis linked to mitochondrial redox imbalance in a subpopulation of quiescent astrocyte-like glioma cells resistant to standard forms of treatment.
Keyphrases